- Previous Close
10.25 - Open
10.40 - Bid 10.80 x --
- Ask 11.20 x --
- Day's Range
10.35 - 11.20 - 52 Week Range
5.98 - 15.00 - Volume
49,736 - Avg. Volume
39,461 - Market Cap (intraday)
274.297M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.44 - Earnings Date Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.50
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
www.corline.seRecent News: CLBIO.ST
View MorePerformance Overview: CLBIO.ST
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLBIO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLBIO.ST
View MoreValuation Measures
Market Cap
274.30M
Enterprise Value
266.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.33
Price/Book (mrq)
3.25
Enterprise Value/Revenue
19.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.02%
Return on Assets (ttm)
-6.25%
Return on Equity (ttm)
-10.80%
Revenue (ttm)
23.48M
Net Income Avi to Common (ttm)
-9.63M
Diluted EPS (ttm)
-0.44
Balance Sheet and Cash Flow
Total Cash (mrq)
7.33M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.28M